secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-06-12T23:59:59+00:00
Accession:  0000950170-25-085479
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia shareholders elect three Class III directors and approve 2025 equity plan
--------------------------------------------------------------------------------

- Elected William Chase, Georgia Keresty, and John M. Leonard as Class III directors for three-year terms ending 2028.
- Approved the 2025 Equity Incentive Plan: 50.8M for, 13.6M against, 93.8K abstentions.
- Ratified Deloitte & Touche as independent auditor for FY2025: 82.1M for, 497.8K against.
- Advisory say-on-pay vote passed (45.8M for, 18.6M against); future votes will be held annually.
- Broker non-votes were 18.3M on director elections, equity plan, and say-on-pay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025085479/0000950170-25-085479-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025085479/ntla-20250611.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-085479

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer